GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WAVE Life Sciences Ltd (STU:1U5) » Definitions » EBITDA Margin %

WAVE Life Sciences (STU:1U5) EBITDA Margin % : 804.55% (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is WAVE Life Sciences EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. WAVE Life Sciences's EBITDA for the three months ended in Sep. 2024 was €-55.64 Mil. WAVE Life Sciences's Revenue for the three months ended in Sep. 2024 was €-6.92 Mil. Therefore, WAVE Life Sciences's EBITDA margin for the quarter that ended in Sep. 2024 was 804.55%.


WAVE Life Sciences EBITDA Margin % Historical Data

The historical data trend for WAVE Life Sciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WAVE Life Sciences EBITDA Margin % Chart

WAVE Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,245.77 -714.23 -286.06 -4,181.71 -51.89

WAVE Life Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.63 -56.79 -257.47 -166.69 804.55

Competitive Comparison of WAVE Life Sciences's EBITDA Margin %

For the Biotechnology subindustry, WAVE Life Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WAVE Life Sciences's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where WAVE Life Sciences's EBITDA Margin % falls into.



WAVE Life Sciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

WAVE Life Sciences's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-53.91/103.901
=-51.89 %

WAVE Life Sciences's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-55.643/-6.916
=804.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WAVE Life Sciences  (STU:1U5) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


WAVE Life Sciences EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of WAVE Life Sciences's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


WAVE Life Sciences Business Description

Traded in Other Exchanges
Address
Marina One East Tower, 7 Straits View No. 12-00, Singapore, SGP, 018936
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

WAVE Life Sciences Headlines

No Headlines